WELL Health Technologies Delays Annual Financial Filings Amid Subsidiary Issues
VANCOUVER, BC, March 28, 2025 /PRNewswire/ – WELL Health Technologies Corp. WELL WHTCF (“WELL” or the “Company“), a digital healthcare firm dedicated to improving health outcomes through technology, has announced a delay in filing its audited annual consolidated financial statements for the year ending December 31, 2024. This delay, which affects the mandatory management discussion and analysis as well as the CEO and CFO certificates (collectively, the “Required Filings“), pushes beyond the March 31, 2025 deadline (the “Deadline“).
The delay arises from accounting issues related to the Company’s non-wholly owned Delaware subsidiary, Circle Medical Technologies, Inc. (“Circle Medical“). In fiscal 2023, Circle Medical reported a net loss of $1.1 million, impacting WELL’s consolidated net income of $16.6 million. Additionally, it contributed less than 2.7% to the Company’s consolidated Adjusted EBITDA(1).
In September 2024, Circle Medical received a request for the voluntary production of documents and information (the “RFI“) from the Civil Division of the U.S. Attorney’s Office for the Northern District of California (“USAO“). This inquiry is focused on certain billing practices of Circle Medical in the U.S. The company is currently working to respond to the RFI and resolve this investigation. Completion of this process is essential for finalizing Circle Medical’s financial statements, and in turn, the Company’s annual consolidated financial statements due December 31, 2024. Unfortunately, this will not be finalized before the March 31, 2025 filing deadline.
WELL Health does not anticipate that resolving this matter will significantly affect its cash position or available resources. Both the Company and Circle Medical are diligently working to finalize the annual consolidated financial statements as soon as possible. They currently project that the Required Filings will be submitted on or before April 15, 2025 (the “Filing Interval“).
Furthermore, the Company is actively exploring strategic alternatives for Circle Medical and remains committed to this process.
WELL Health has requested a management cease trade order from the British Columbia Securities Commission, its principal regulator, as per National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“). While approval of this order is not guaranteed, if it is granted, it will not restrict trading in securities by individuals who are not part of the Company’s management.
The Company plans to comply with the alternative information guidelines outlined in NP 12-203 by issuing bi-weekly status reports, if necessary, until it resolves the filing default. Failure to file the Required Filings in time could result in the British Columbia Securities Commission imposing a general cease trade order against WELL.
Aside from the matters disclosed, WELL remains up to date with its filing obligations.
Footnote: |
|
1. |
Non-GAAP Financial Measures – Adjusted EBITDA |